Chiasma, Inc. (NASDAQ:CHMA) Q2 2020 Earnings Conference Call - Preliminary Transcript
Aug 10, 2020 • 05:00 pm ET
Thank you for standing by. This is the conference operator. Welcome to the Chiasma's second quarter 2020 earnings conference call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator Instructions].
I would now like to turn the conference over to Glenn Garmont, Investor Relations. Please go ahead.
Thank you operator. Welcome to our conference call. Today, we issued our second quarter 2020 operating and financial results press release, a copy of which may be found on our website.
During this call, we will be making certain forward-looking statements about events and circumstances, including but not limited to statements concerning our plans and expectations for the commercialization of MYCAPSSA, including its reimbursement and market adoption, the size and composition of the U.S. market for MYCAPSSA, the commercial or therapeutic potential MYCAPSSA and anticipated market acceptance of MYCAPSSA, our expectations regarding the manufacturing supplement that we submitted to FDA for MYCAPSSA and our plans to submit an additional manufacturing supplement and expectations regarding the availability of product supply, the timing and success of a potential commercial launch of MYCAPSSA in the United States, our ability to convert endocrinologists and patients to MYCAPSSA from octreotide and lanreotide injections, our plans concerning the number of customer-facing employees and the timing of their hiring, our expectations regarding financial results and the potential receipt of additional funds under our royalty agreement with HealthCare Royalty Partners and the timing of topline results from the MPOWERED trial and potential application for EU marketing approval.
These statements are based on current expectations and information available to us. You should not place undue reliance on these statements. We may not achieve our goals, carry out our plans or intentions or meet expectations. Actual results or events may differ materially due to numerous risks and uncertainties, including those detailed in the Risk Factors section of our Form 10-Q filed with the SEC for the quarter ended June 30, 2020, as well as our subsequent filings with the SEC. We encourage everyone to read these documents. Except as required by law, Chiasma disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise.
Joining the call today is Raj Kannan, Chief Executive Officer, Anand Varadan, Executive Vice President and Chief Commercial Officer, Bill Ludlam, Senior Vice President of Clinical Development and Medical Affairs and Mark Fitzpatrick, President and Principal Financial Officer.
Now I would like to turn the call over to Chiasma's Chief Executive Officer, Raj Kannan. Raj?
Thanks Glenn. And thank you everyone for joining the call today. We have been very productive during the second quarter, both preparing for the commercial launch of MYCAPSSA in the U.S. while in parallel continuing to advance our MPOWERED Phase 3 trial to support the potential approval of MYCAPSSA in the European Union. I wanted to highlight three areas in my review of the second quarter,